



**Joint Position Statement on
The Clinical Use of Non-Invasive Preimplantation Genetic Testing (niPGT)
by Indian Assisted Reproduction Societies**

The Indian Society for Assisted Reproduction (ISAR), Indian Fertility Society (IFS), and Academy of Clinical Embryologists (ACE) jointly recommend that Non-Invasive Preimplantation Genetic Testing (niPGT), whether using spent culture media or blastocoel fluid should not be used in clinical practice at this time and does not recommended it for embryo ranking or selection for transfer in its present form. It has based this position statement on the following key considerations:

- **Diagnostic Accuracy:** Current evidence indicates significant error rates, including unacceptably high false positives and false negatives, which undermine its reliability for clinical decision-making.
- **Clinical Efficacy:** There is a lack of conclusive evidence that niPGT improves clinical outcomes such as implantation rates, pregnancy rates, or live birth rates.

The IFS, ISAR, and ACE urge the medical and scientific communities to focus on research on niPGT to ensure its reliability and clinical applicability in the future.

Dr Ameet Patki
President

**Indian Society for Assisted
Reproduction**

Dr Pankaj Talwar
President

Indian Fertility Society

Dr Sujatha Ramakrishnan
President

**Academy of Clinical
Embryologists**

Prepared by the joint working group of ISAR, IFS, ACE.

Dr. Deepak Modi, Dr. Gaurav Majumdar, Dr. Sayali Kandari, Dr. Varsha Samson Roy, Dr. Parasuram Gopinath, Dr. Asha Baxi, Dr. Vanshika Jain

All correspondences should be addressed to

isar.office@gmail.com, indianfertilitysocietydelhi@gmail.com, admin@theaceorg.in

Release date June 16 2025